WO2012036392A3 - 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 - Google Patents

인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 Download PDF

Info

Publication number
WO2012036392A3
WO2012036392A3 PCT/KR2011/006370 KR2011006370W WO2012036392A3 WO 2012036392 A3 WO2012036392 A3 WO 2012036392A3 KR 2011006370 W KR2011006370 W KR 2011006370W WO 2012036392 A3 WO2012036392 A3 WO 2012036392A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
growth factor
epidermal growth
fab antibody
factor receptor
Prior art date
Application number
PCT/KR2011/006370
Other languages
English (en)
French (fr)
Other versions
WO2012036392A2 (ko
Inventor
차상훈
Original Assignee
주식회사 아이지세라피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아이지세라피 filed Critical 주식회사 아이지세라피
Publication of WO2012036392A2 publication Critical patent/WO2012036392A2/ko
Publication of WO2012036392A3 publication Critical patent/WO2012036392A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 인간 항-상피세포성 성장인자수용체 Fab 항체에 관한 것이다. 본 발명에서 DVS-II방법에 의해 선별된 고 친화도 항-EGFR 인간 Fab 항체는 스크리닝에 의해 선별된 중사슬 가변영역 및 경사슬 가변영역을 포함하는 것으로써, 상피세포성 성장인자 수용체에 대하여 특이성이 높아서, 종양 치료용 약학 조성물 및 직장암 치료용 약학조성물을 제공할 수 있다.
PCT/KR2011/006370 2010-09-17 2011-08-29 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 WO2012036392A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0091658 2010-09-17
KR1020100091658A KR101273918B1 (ko) 2010-09-17 2010-09-17 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
WO2012036392A2 WO2012036392A2 (ko) 2012-03-22
WO2012036392A3 true WO2012036392A3 (ko) 2012-05-10

Family

ID=45832045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006370 WO2012036392A2 (ko) 2010-09-17 2011-08-29 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물

Country Status (2)

Country Link
KR (1) KR101273918B1 (ko)
WO (1) WO2012036392A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016171365A1 (ko) * 2015-04-23 2016-10-27 신일제약주식회사 Egfr에 특이적으로 결합하는 fab단편

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025167A1 (en) * 1994-03-17 1995-09-21 Merck Patent Gmbh Anti-egfr single-chain fvs and anti-egfr antibodies
WO2002030984A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025167A1 (en) * 1994-03-17 1995-09-21 Merck Patent Gmbh Anti-egfr single-chain fvs and anti-egfr antibodies
WO2002030984A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US20020058033A1 (en) * 2000-10-13 2002-05-16 Raisch Kevin Paul Human anti-epidermal growth factor receptor single-chain antibodies
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Also Published As

Publication number Publication date
WO2012036392A2 (ko) 2012-03-22
KR101273918B1 (ko) 2013-06-13
KR20120118516A (ko) 2012-10-29

Similar Documents

Publication Publication Date Title
WO2013006547A3 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
NZ604007A (en) Monoclonal antibodies against her2 epitope
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
WO2014004427A3 (en) Anti-egfr antibodies and uses thereof
WO2013163631A3 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013164689A8 (en) Humanized pan-her antibody compositions
NZ594665A (en) Bispecific anti-her antibodies
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
JOP20110402B1 (ar) الأجسام المضادة ل cd38
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
WO2011123489A3 (en) Anti-cd40 antibodies
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
EP2582722A4 (en) ANTIBODIES AGAINST GD2
SI2766040T1 (sl) Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
NZ611785A (en) Anti-notch1 antibodies
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
IL213975A0 (en) Treatment of cancer with a humanized anti-egfr igg1 antibody and inriotecan
WO2013004076A8 (zh) Agr2阻断抗体及其用途
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011156617A3 (en) Anti-egfr antibodies
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
WO2013003037A3 (en) Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
EP2502936A4 (en) HIGHLY FUNCTIONAL MUTANT OF VARIABLE REGION OF HUMANIZED ANTI-EGFR ANTIBODIES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825352

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, DATED 11.07.13

122 Ep: pct application non-entry in european phase

Ref document number: 11825352

Country of ref document: EP

Kind code of ref document: A2